Skip Navigation

Annals of Oncology 2006 17(12):1727-1729; doi:10.1093/annonc/mdl433
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ng, A.
Right arrow Articles by Mauch, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ng, A.
Right arrow Articles by Mauch, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

editorials

The impact of treatment on the risk of second malignancy after Hodgkin's disease

AK Ng and PM Mauch*

Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

* (E-mail: pmauch@lroc.harvard.edu)

The first 10% of the full text of this article appears below.

In the last several decades, there has been a steady improvement in the cure rate of patients diagnosed with Hodgkin's disease as more effective treatment and more accurate staging techniques become available [1]. With the growing number of patients surviving Hodgkin's disease, various delayed complications are being increasingly recognized. Second malignancy after Hodgkin's disease, first reported in the early 1970s [2], is one of the most serious late effects and is the leading cause of death in long-term survivors of Hodgkin's disease [3, 4]. The elevated risk has largely been attributed to leukemogenic or carcinogenic effects of the treatments for Hodgkin's disease. There are likely other contributing factors, however, including an impaired immune system related to treatments or the disease itself and genetic susceptibility in some of the patients.

. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
Y. Lorenzo, M. Provencio, L. Lombardia, R. Diaz, J. Silva, M. Herrera, J. M. Garcia, C. Pena, V. Garcia, J. Romero, et al.
Differential Genetic and Functional Markers of Second Neoplasias in Hodgkin's Disease Patients
Clin. Cancer Res., August 1, 2009; 15(15): 4823 - 4828.
[Abstract] [Full Text] [PDF]